<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04519905</url>
  </required_header>
  <id_info>
    <org_study_id>ESO-Shanghai15</org_study_id>
    <nct_id>NCT04519905</nct_id>
  </id_info>
  <brief_title>Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)</brief_title>
  <official_title>Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Huadong Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangsu Cancer Institute &amp; Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gansu Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Xiamen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taihe Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuxi No. 4 People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ningbo No.2 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      So far, there is no specific clinical guideline for elderly patients (&gt;75 yr) with esophageal&#xD;
      squamous cell carcinoma (ESCC). Patients with locally advanced ESCC were enrolled and&#xD;
      randomly assigned to either definitive radiotherapy group (61.2Gy/34Fx） or the&#xD;
      chemoradiotherapy group (50.4Gy/28Fx；Paclitaxel plus carboplatin). The primary end point was&#xD;
      3-year overall survival (OS). The second end points included life quality, radiation side&#xD;
      effects and 3-yr cancer specific survival.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to now, definitive radiotherapy was major treatment plan for elderly ESCC patients.&#xD;
      However, whether elective elderly patients can obtain survival benefits through&#xD;
      chemoradiotherapy is not clear. Thus we design the clinical trail to answer the question.&#xD;
&#xD;
      Three hundred and twenty elderly patients with ESCC would be recruited. There are two&#xD;
      stratification factors including 80 years old and lymph node metastasis. The patients in the&#xD;
      chemoradiotherapy group were treated with paclitaxel (45mg/m2) and carboplatin (AUC=2) one&#xD;
      cycle per week for five cycles.The primary end point was 3-year overall survival (OS). The&#xD;
      second end points included life quality, radiation side effects and 3-yr cancer specific&#xD;
      survival. The life quality questionnaire included QlQ-C30 and OES-18.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 6, 2020</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival difference of definitive radiotherapy and chemoradiotherapy groups</measure>
    <time_frame>3-year</time_frame>
    <description>The time between the start of the study treatment (Day 1) and death from any cause or last follow-up for patients alive at the end of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>difference of quality of life between different groups</measure>
    <time_frame>the period of treatment within 7 weeks and follow up time with an average of 3months</time_frame>
    <description>Assess the quality of life through life quality questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>radiation side effects</measure>
    <time_frame>acute side effects within 3 months, late side effects for 3 months later</time_frame>
    <description>Record the radiation side effects including acute and late side effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cancer specific survival</measure>
    <time_frame>3-year</time_frame>
    <description>The time between the start of the study treatment (Day 1) and death from tumor or last follow-up for patients alive at the end of the study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <condition>Chemoradiotherapy</condition>
  <condition>Survival</condition>
  <arm_group>
    <arm_group_label>chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50.4Gy/28Fx; Paclitaxel plus carboplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>61.2Gy/34Fx</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel plus carboplatin</intervention_name>
    <description>Paclitaxel （45mg/m2) plus carboplatin (AUC=2); five cycles; qw</description>
    <arm_group_label>chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>Different radiotherapy dose in different groups.</description>
    <arm_group_label>chemoradiotherapy</arm_group_label>
    <arm_group_label>radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Indicates no limit on eligibility based on the sex of participants&#xD;
&#xD;
          -  The 76 years old for the minimum age a potential participant must meet to be eligible&#xD;
             for the clinical study.&#xD;
&#xD;
          -  Esophageal squamous cell carcinoma confirmed by pathology&#xD;
&#xD;
          -  No radiotherapy, chemotherapy or other treatments prior to enrollment&#xD;
&#xD;
          -  Local advanced esophageal squamous cell carcinoma (T2-4N0-1M0-1a, TxN1M0-1a, TxNxM1a,&#xD;
             TxNxM1b (M1b only for supraclavicular lymph node metastasis) (AJCC 6th)&#xD;
&#xD;
          -  Use of an effective contraceptive for adults to prevent pregnancy&#xD;
&#xD;
          -  No severely abnormal hematopoietic, cardiac, pulmonary, renal, or hepatic function&#xD;
&#xD;
          -  No immunodeficiency&#xD;
&#xD;
          -  ECOG 0-1.&#xD;
&#xD;
          -  Life expectancy of more than 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Total radiotherapy dose cannot reach 61.2Gy/34Fx&#xD;
&#xD;
          -  Esophageal perforation, or hematemesis&#xD;
&#xD;
          -  History of radiotherapy or chemotherapy for esophageal cancer&#xD;
&#xD;
          -  History of surgery within 28 days before Day 1&#xD;
&#xD;
          -  History of prior malignancies (other than skin basal cell carcinoma or cervical&#xD;
             carcinoma in situ with a disease-free survival of at least 3 years)&#xD;
&#xD;
          -  Participation in other interventional clinical trials within 30 days&#xD;
&#xD;
          -  Pregnant or breast-feeding women or fertile patients&#xD;
&#xD;
          -  Drug addiction,&#xD;
&#xD;
          -  alcoholism or AIDS&#xD;
&#xD;
          -  Uncontrolled seizures or psychiatric disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>76 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kuaile Zhao, doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiangpeng Zheng, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huadong Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kuaile Zhao, doctor</last_name>
    <phone>18017312534</phone>
    <phone_ext>021-64175590</phone_ext>
    <email>kuaile_z@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ying jia Deng, doctor</last_name>
    <phone>18017312829</phone>
    <email>dengjiaying3@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jiangsu Cancer Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinjun C Ye, M.D.</last_name>
      <phone>13585175433</phone>
      <phone_ext>13585175433</phone_ext>
      <email>jjye2004@163.com</email>
    </contact>
    <investigator>
      <last_name>Jinjun C Ye, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huadong Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiangpeng Zheng, M.D.</last_name>
      <phone>8621-62483180</phone>
      <phone_ext>862162483180</phone_ext>
      <email>zhengxp@fudan.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Xiangpeng Zheng</last_name>
      <phone>862162483180</phone>
      <phone_ext>862162483180</phone_ext>
      <email>zhengxp@fudan.edu.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Xiangpeng Zheng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fudan Universtiy Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kuaile Zhao, MD</last_name>
      <phone>18017312534</phone>
      <email>kuaile_z@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 12, 2020</study_first_submitted>
  <study_first_submitted_qc>August 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>October 31, 2021</last_update_submitted>
  <last_update_submitted_qc>October 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>esophageal squamous cell carcinoma</keyword>
  <keyword>elderly patients</keyword>
  <keyword>chemoradiotherapy</keyword>
  <keyword>definitive radiotherapy</keyword>
  <keyword>survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

